Circulating CD34+ cells, metabolic syndrome, and cardiovascular risk

Circulating CD34+ cells, metabolic syndrome, and cardiovascular risk
复制标题

DOI:
10.1093/eurheartj/ehl198
复制
发表时间:
2006-09-01
影响因子:
39.3
通讯作者:
Avogaro, Angelo
Avogaro, Angelo
中科院分区:
医学1区
文献类型:
--
作者:
Fadini, Gian Paolo;Vigili de Kreutzenberg, Saula;Avogaro, Angelo

文献摘要

被引文献

相似文献

循环祖细胞被认为参与心血管(CV)稳态,它们的耗竭与CV损伤有关。作为一般协议,他们的表征是缺乏的,这项工作进行了评估祖细胞和CV风险的不同抗原谱之间的关系,特别是关于代谢综合征(MetSyn)。方法和结果CD 34,CD 133,和KDR被用来量化循环祖细胞在214个受试者在不同水平的CV风险。在6种不同细胞亚型(CD34(+)、CD133(+)、CD34(+)CD133(+)、CD34(+)KDR(+)、CD133(+)KDR(+)和CD34(+)CD133(+)KDR(+))的交叉分析中,CD34(+)祖细胞与CV参数和风险估计值的相关性最好。MetSyn的组分均以减少CD34(+)细胞为特征,并在减少CD34(+)细胞计数中协同作用。结论CD34(+)细胞计数可识别与心血管危险性相关的祖细胞,CD34(+)细胞与心血管危险性呈负相关,且聚集代谢成分具有协同作用。祖细胞计数可用作CV风险的替代标志物,而广泛的抗原表征可能不适用于此目的。
Aims Circulating progenitor cells are believed to participate in cardiovascular (CV) homeostasis and their exhaustion has been linked to CV damage. As general agreement on their characterization is lacking, this work was carried out to assess the relationships between different antigenic profiles of progenitor cells and CV risk, with special regard to metabolic syndrome (MetSyn).Methods and results CD34, CD133, and KDR were used to quantify circulating progenitors in 214 subjects at different levels of CV risk. In a cross-analysis of six different cell subtypes (CD34(+), CD133(+), CD34(+)CD133(+), CD34(+)KDR(+), CD133(+)KDR(+), and CD34(+)CD133(+)KDR(+)), CD34(+) progenitors showed the best correlation with CV parameters and risk estimates. Components of the MetSyn were all characterized by reduction of CD34(+) cells and acted synergistically in decreasing CD34(+) cell count. Moreover, CD34(+) cell count demonstrated a high performance in detecting high CV risk.Conclusion These data demonstrate that CD34 identifies progenitor cells linked to CV risk, showing a close negative correlation between CD34(+) cells and CV risk, as well as a synergic detrimental effect of clustered metabolic components. Progenitor cell count may be used as a surrogate marker of CV risk, whereas extensive antigenic characterization may not be useful for this purpose.